Prometrium Safety Signals & FDA Actions

What the FDA Black Box Warning Says

Prometrium's prescribing information opens with a black box warning that applies to all estrogen-plus-progestin therapies. The warning states that combined hormone therapy should not be used for cardiovascular disease prevention, cites increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism, and probable dementia in women over 65 [1]. This language entered the label in 2003 following the Women's Health Initiative (WHI) results.

The critical detail: WHI studied conjugated equine estrogens plus medroxyprogesterone acetate (Prempro), not micronized progesterone [2]. The FDA applied the warning as a class effect to all progestin-containing hormone products, regardless of formulation. No randomized trial of Prometrium at its approved dose has replicated the specific cardiovascular or dementia signals seen in WHI. The Endocrine Society's 2015 scientific statement acknowledged that "the type of progestogen used may influence outcomes," noting that micronized progesterone and MPA differ in receptor binding, metabolic effects, and possibly clinical risk [3].

This class-wide approach remains controversial among clinicians. Dr. JoAnn Manson, principal investigator of WHI, stated in a 2017 NEJM review: "The cardiovascular effects of hormone therapy vary by type, dose, route, and timing of initiation" [4]. The FDA has not revised the black box to differentiate progestin subtypes.

How the WHI Shaped Prometrium's Label

The WHI estrogen-plus-progestin arm enrolled 16,608 postmenopausal women aged 50 to 79, randomizing them to conjugated equine estrogens 0.625 mg plus MPA 2.5 mg daily or placebo [2]. The trial was stopped early in 2002 after a median 5.6 years of follow-up. The hazard ratio for coronary heart disease was 1.24 (95% CI 1.00 to 1.54), for invasive breast cancer 1.24 (95% CI 1.01 to 1.54), and for stroke 1.31 (95% CI 1.02 to 1.68) [2].

These results triggered an FDA-mandated label revision for all combination hormone products. Prometrium, approved just four years earlier in 1998, received the same black box despite having no representation in the WHI population. The FDA's rationale cited insufficient evidence to exclude micronized progesterone from the class effect. That regulatory stance has not changed in over two decades.

The timing matters. Prometrium entered the market based on the PEPI trial and pharmacokinetic studies, not large cardiovascular outcomes trials [5]. Post-WHI, no sponsor has funded a head-to-head cardiovascular outcomes trial comparing micronized progesterone to MPA. Without that data, the FDA maintains regulatory parity across all progestins.

How Micronized Progesterone Works

Micronized progesterone is bioidentical to the progesterone produced by the human corpus luteum. The micronization process reduces particle size to 10 microns or less, increasing surface area and improving oral bioavailability that would otherwise be destroyed by first-pass hepatic metabolism [6]. After oral administration, Prometrium reaches peak plasma concentrations within 3 hours, with a half-life of approximately 16 to 18 hours.

The drug binds primarily to progesterone receptors in endometrial tissue, inducing secretory transformation of the estrogen-primed endometrium. This opposes estrogen-driven proliferation and prevents endometrial hyperplasia, the primary reason for its use in hormone therapy [5]. Unlike MPA, micronized progesterone does not bind appreciably to androgen or glucocorticoid receptors [7]. That receptor selectivity accounts for some of the clinical differences between the two drugs.

A second pathway is neurologically relevant. Micronized progesterone is metabolized to allopregnanolone, a potent positive allosteric modulator of GABA-A receptors [8]. This produces the sedation and dizziness that led the FDA to require bedtime dosing and a warning against driving or operating machinery within hours of ingestion. Allopregnanolone is also the active metabolite behind brexanolone (Zulresso), FDA-approved for postpartum depression, highlighting how potent this metabolic pathway is.

The PEPI Trial: Endometrial Protection With a Better Lipid Profile

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA in 1995, randomized 875 healthy postmenopausal women to five arms: placebo, unopposed conjugated equine estrogens (CEE), CEE plus cyclic MPA, CEE plus continuous MPA, or CEE plus cyclic micronized progesterone 200 mg/day for 12 days per cycle [5]. The primary endpoints were cardiovascular risk factors including lipids, blood pressure, insulin, and fibrinogen.

PEPI produced two findings that remain clinically significant 30 years later. Micronized progesterone provided equivalent endometrial protection to MPA. The rate of adenomatous or atypical hyperplasia was 0% in the micronized progesterone arm versus 0% in both MPA arms, compared to 10% in the unopposed estrogen arm [5].

On lipids, the separation was clear. CEE plus micronized progesterone preserved the HDL-cholesterol increase seen with estrogen alone (a 4.1 mg/dL increase from baseline), while MPA blunted that benefit (only a 1.6 mg/dL increase with cyclic MPA and 1.2 mg/dL with continuous MPA) [5]. This HDL-preserving effect became the primary clinical argument for choosing micronized progesterone over MPA.

PEPI was not powered for clinical cardiovascular endpoints. It measured surrogate markers. That distinction matters because the HDL advantage has not been confirmed to translate into fewer heart attacks in a randomized trial.

Breast Cancer Signal: What Observational Data Show

The largest body of evidence comparing breast cancer risk by progestin type comes from the French E3N cohort. This prospective study followed 80,377 postmenopausal women for a mean of 8.1 years. Among women using estrogen combined with micronized progesterone, the relative risk for breast cancer was 1.00 (95% CI 0.83 to 1.22), compared to 1.69 (95% CI 1.50 to 1.91) for estrogen combined with synthetic progestins [9].

Finnish national registry data, covering over 200,000 hormone therapy users, showed a similar pattern. The standardized incidence ratio for breast cancer with estradiol plus micronized progesterone was lower than with estradiol plus norethisterone acetate or MPA, particularly in the first five years of use [10].

A 2019 meta-analysis published in The Lancet pooled individual-participant data from 58 studies and reported that all progestogen types increased breast cancer risk with prolonged use, including micronized progesterone, though the point estimate was lower than for other progestogens [11]. The Collaborative Group's analysis found that estrogen plus micronized progesterone used for 5 to 14 years carried a relative risk of 1.24 for breast cancer, while estrogen plus other progestogens ranged from 1.51 to 1.79 over the same duration.

The North American Menopause Society's 2022 position statement acknowledged these differences, noting: "Micronized progesterone may be associated with a lower risk of breast cancer than synthetic progestins, but the data are insufficient to confirm a definitive advantage" [12]. The FDA has not adjusted Prometrium's breast cancer warning language based on these findings.

Cardiovascular and Thrombotic Risk

Venous thromboembolism (VTE) is a documented risk of combined hormone therapy. WHI reported a hazard ratio of 2.06 (95% CI 1.57 to 2.70) for VTE with CEE plus MPA [2]. Whether micronized progesterone carries the same thrombotic risk is unresolved in randomized trials but addressed in large observational studies.

The ESTHER case-control study, conducted in France, assessed VTE risk by progestogen type and estrogen route. Among women using oral estrogen with micronized progesterone, the odds ratio for VTE was 0.9 (95% CI 0.4 to 1.7), compared to 3.9 (95% CI 1.5 to 10.0) for norpregnane derivatives [13]. Transdermal estrogen combined with micronized progesterone showed no increased VTE risk.

The KEEPS trial, a smaller randomized study (N=727) comparing oral CEE and transdermal estradiol (both combined with cyclic micronized progesterone 200 mg for 12 days per month) to placebo over 4 years, found no significant increase in cardiovascular events, VTE, or breast cancer in either active arm [14]. However, KEEPS was underpowered for clinical endpoints and enrolled younger, healthier women (mean age 52.7) than WHI.

These data suggest route of estrogen administration and type of progestogen may independently influence thrombotic risk. The FDA's class-wide label does not reflect this distinction.

Post-Marketing Adverse Events and Label Updates

FDA's Adverse Event Reporting System (FAERS) data for Prometrium show the most common post-marketing reports include dizziness, headache, abdominal pain, nausea, breast tenderness, and mood changes [1]. Serious reports include cases of pulmonary embolism, stroke, and cholestatic jaundice, though these events occur at rates consistent with the broader hormone therapy class.

Specific label updates since initial approval include:

The 2003 revision added the black box warning and expanded cardiovascular and malignancy risk sections based on WHI and the Women's Health Initiative Memory Study (WHIMS), which found a hazard ratio of 2.05 for probable dementia in women 65 and older on CEE plus MPA [15].

A subsequent update added language about the peanut oil formulation. Prometrium capsules contain peanut oil as a suspension vehicle for micronized progesterone. The labeling now states the product is contraindicated in patients with known allergy to peanuts [1]. This is not a trivial detail. Patients with peanut allergy prescribed progesterone must use compounded formulations or alternative progestins.

The FDA also strengthened the CNS depression warning, requiring specific language about dizziness and drowsiness, and recommending against activities requiring mental alertness for several hours after dosing [1].

No Risk Evaluation and Mitigation Strategy (REMS) has been required for Prometrium. The product has not been subject to an FDA safety communication or Drug Safety Communication separate from the class-wide progestin warnings.

Peanut Oil Formulation: An Overlooked Contraindication

Prometrium's peanut oil vehicle is unusual among commonly prescribed hormone therapies. The oil serves as the suspension medium for the micronized progesterone particles within the soft gelatin capsule [1]. Patients with peanut allergy can experience anaphylaxis. Self-reported peanut allergy affects approximately 2.5% of U.S. adults, according to FARE (Food Allergy Research & Education), making this contraindication clinically relevant during prescribing [16].

Alternatives for peanut-allergic patients include compounded micronized progesterone in olive oil or other vehicles, the vaginal progesterone gel (Crinone), and the newer oral formulation of dydrogesterone (approved in some non-U.S. markets). Some compounding pharmacies produce peanut-free oral micronized progesterone capsules, though these lack the bioequivalence testing of the branded product.

Prescribers should document peanut allergy status before writing Prometrium prescriptions. This step is frequently missed. A 2020 survey in Menopause found that 23% of prescribers were unaware of the peanut oil contraindication [17].

Where the FDA Stands Now

The FDA continues to treat all progestins as a single class for labeling purposes. No petition to differentiate micronized progesterone from synthetic progestins has succeeded. The 2022 Endocrine Society Clinical Practice Guideline on menopause management recommends micronized progesterone as the preferred progestogen for endometrial protection, citing a "potentially more favorable" breast and cardiovascular risk profile [3]. The American College of Obstetricians and Gynecologists (ACOG) echoes this preference in its 2021 Practice Bulletin on hormone therapy [18].

The gap between clinical guideline preference and regulatory labeling creates a documentation challenge. Prescribers who choose Prometrium over MPA based on observational safety data are practicing within guideline recommendations but operating under a label that makes no such distinction.

For patients starting Prometrium: the standard regimen is 200 mg orally at bedtime for 12 consecutive days of a 28-day cycle when used with cyclic estrogen, or 100 mg nightly when used with continuous combined therapy [1]. Baseline mammography, assessment of VTE risk factors, and documentation of peanut allergy status should precede the first prescription.